Omicron blunts rise in vaccine sales for 2022, health analytics firm says
jonathanfilskov-photography/E+ via Getty Images


Although sales of COVID-19 vaccines this year will rise above 2021's total, the increase is now less than earlier projected due to the mildness of disease caused by the Omicron variant, according to Airfinity.
The London-based health intelligence and analytics firm says that sales of COVID vaccines in 2022, except China and India, will rise to ~$85B, about 28% lower than a previous $118B estimate.

The firm estimates that COVID vaccine sales for non-Chinese vaccines reached $65.6B in 2021.
Airfinity told Bloomberg that optimism that the worst of the pandemic is behind us will likely stem some purchases of vaccines from richer countries.
Regarding boosters, Airfinity says that booster programs in wealthy countries would help propel sales. It estimates booster sales will rise ~30% in 2022 from ~$66B last year.
Vaccine names: Moderna (MRNA
-7.9%), BioNTech (BNTX
-5.8%), Novavax (NVAX
-15.5%), Johnson & Johnson (JNJ
-2.2%), Pfizer (PFE
-4.4%), and AstraZeneca (AZN
-5.2%).
The uncertain future for demand of booster shots could have an impact on some vaccine manufacturers.